22 recruiting, 19 completed, 14 not yet recruiting, 7 active not recruiting. 22 Phase 2, 14 Phase 1, 8 Not applicable, 5 Phase 3, 1 Early Phase 1.
Follow Idiopathic Pulmonary Fibrosis (IPF): new trials by email Literature Review of Idiopathic Pulmonary Fibrosis (IPF) trials Research Report on Idiopathic Pulmonary Fibrosis (IPF)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of AGMB-447 in Participants With Idiopathic Pulmonary Fibrosis AGMB-447, Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Not yet recruiting | Agomab Spain S.L.U. | 120 | 2026-11-30 | 2026-10-07 |
| A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis AK3280, Placebo, Pirfenidone - Idiopathic Pulmonary Fibrosis (IPF) | Phase 3 | Not yet recruiting | Shanghai Ark Biopharmaceutical Co., Ltd. | 263 | 2026-08-31 | 2026-07-22 |
| Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis HSK50042 dose 1, HSK50042 dose 2, HSK50042 dose 3 - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Not yet recruiting | Haisco Pharmaceutical Group Co., Ltd. | 175 | 2026-08-25 | 2026-07-27 |
| A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung | Not yet recruiting | Cosmos Rx, Inc | 100 | 2026-07-01 | 2026-05-29 | |
| Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF) Deupirfenidone, Pirfenidone (PFD) - Idiopathic Pulmonary Fibrosis (IPF) | Phase 3 | Recruiting | PureTech | 1100 | 2026-06-26 | 2026-09-03 |
| A Phase IIb Study to Evaluate AZD8965 in Participants With IPF. Placebo for AZD8965, AZD8965 low dose, AZD8965 medium dose - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Recruiting | AstraZeneca | 359 | 2026-06-11 | 2026-09-21 |
| A Phase I Study of HW241045 in Healthy Subjects HW241045 Formulation A, HW241045 Formulation B, Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 1 | Not yet recruiting | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | 102 | 2026-06-01 | 2026-05-18 |
| Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis Nintedanib Dry Powder Inhalation, Placebo - Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Recruiting | Mannkind Corporation | 153 | 2026-05-15 | 2026-09-14 |
| Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF) Nintedanib,Dextromethorphan, Nintedanib,Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 60 | 2026-05-12 | 2026-05-13 |
| Safety and Efficacy of Nebulized 3D-cultured Human Placental Mesenchymal Stem Cell-derived Extracellular Vesicles (hPMSC-EVs) for Idiopathic Pulmonary Fibrosis 3D-cultured human placental mesenchymal stem cell-derived extracellular vesicles - Idiopathic Pulmonary Fibrosis (IPF) | Phase 1 | Not yet recruiting | Huan Ye | 9 | 2026-05-01 | 2026-04-07 |
| Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis BC006, Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Recruiting | Dragonboat Biopharmaceutical Company Limited | 96 | 2026-04-27 | 2026-05-13 |
| Identification of Diagnostic and Prognostic Biomarkers in the Pathological Continuum of Bronco Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Pulmonary Neoplasia Peripheral Blood Collection - COPD, Idiopathic Pulmonary Fibrosis (IPF) | Not applicable | Recruiting | Fondazione Don Carlo Gnocchi ETS | 120 | 2026-04-22 | 2026-07-16 |
| Occupational and Environmental Exposures Analysis in Interstitial Lung Diseases. standard interview - Interstitial Lung Disease Due to Systemic Disease (Disorder), Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder) | Active not recruiting | Istituto Clinico Humanitas | 1000 | 2026-04-01 | 2026-05-11 | |
| Hereditary Influences on Pulmonary Fibrosis Trajectories Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder), Idiopathic Pulmonary Fibrosis (IPF) | Active not recruiting | Istituto Clinico Humanitas | 250 | 2026-04-01 | 2026-05-12 | |
| AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF AP02, Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Recruiting | Avalyn Pharma Inc. | 160 | 2026-03-10 | 2026-10-15 |
| Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial Standard ILD Follow-Up Pathway, Optimized One-Day ILD Follow-Up Circuit - Interstitial Lung Disease (ILD), Fibrotic Interstitial Lung Disease | Not applicable | Active not recruiting | Hospital de Granollers | 152 | 2026-03-09 | 2026-10-21 |
| Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial Standard ILD Diagnostic Pathway, Optimized ILD Diagnostic Circuit - Interstitial Lung Disease (ILD), Suspected Interstitial Lung Disease | Not applicable | Recruiting | Hospital de Granollers | 92 | 2026-03-09 | 2026-10-21 |
| Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell Therapy REGEND007 Cell Therapy - Idiopathic Pulmonary Fibrosis (IPF) | Early Phase 1 | Not yet recruiting | Regend Therapeutics | 12 | 2026-02-15 | 2026-01-22 |
| A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis LTI-03, Dry Powder Inhaler, Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Recruiting | Rein Therapeutics | 120 | 2026-02-02 | 2026-10-16 |
| Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases. Quercetin (dietary supplement), Usual treatment - Fibrotic Interstitial Lungs Diseases, Idiopathic Pulmonary Fibrosis (IPF) | Not applicable | Recruiting | Katerina M. Antoniou | 100 | 2026-01-26 | 2026-03-12 |
Showing 20 of 67. Sign in to see all of them.
Idiopathic Pulmonary Fibrosis (67) · Lung Diseases, Interstitial (16) · Pulmonary Fibrosis (9) · Fibrosis (4) · Lung Diseases (4) · Pathologic Processes (3) · Pulmonary Disease, Chronic Obstructive (3) · Bronchiectasis (2) · Hypertension, Pulmonary (2) · Respiratory Tract Diseases (2) · Alveolitis, Extrinsic Allergic (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Connective Tissue Diseases (1)
Respiratory Tract Diseases (65) · Lung Diseases (63) · Pulmonary Fibrosis (58) · Lung Diseases, Interstitial (51) · Pathological Conditions, Signs and Symptoms (14) · Pathologic Processes (10) · Disease Attributes (5) · Fibrosis (5) · Chronic Disease (4) · Immune System Diseases (4) · Hypersensitivity (3) · Lung Diseases, Obstructive (3) · Behavior (2) · Bronchial Diseases (2) · Cardiovascular Diseases (2)
pirfenidone (4) · Quercetin (2) · Air (1) · Blood Specimen Collection (1) · Dasatinib (1) · Dextromethorphan (1) · Dietary Supplements (1) · Dry Powder Inhalers (1) · GB-0139 (1) · Medicine, Chinese Traditional (1) · Motivational Interviewing (1) · Oxygen (1) · Surveys and Questionnaires (1) · Thalidomide (1) · compound 21 (1)
Hospital de Granollers (3) · Istituto Clinico Humanitas (3) · Avalyn Pharma Inc. (2) · Bristol-Myers Squibb (2) · Haisco Pharmaceutical Group Co., Ltd. (2) · Henan University of Traditional Chinese Medicine (2) · InSilico Medicine Hong Kong Limited (2) · Mannkind Corporation (2) · University of Colorado, Denver (2) · Agomab Spain S.L.U. (1) · Angion Biomedica Corp (1) · Assiut University (1) · AstraZeneca (1) · Azienda Unita Sanitaria Locale di Piacenza (1) · Beijing Tide Pharmaceutical Co., Ltd (1)
United States (21) · China (14) · Italy (9) · United Kingdom (9) · Canada (7) · Germany (7) · Spain (7) · Australia (6) · Poland (5) · Turkey (Türkiye) (5) · South Korea (4) · Argentina (3) · Denmark (3) · France (3) · Greece (3)
Francesco Amati, MD (3) · Jaume Bordas-Martinez, MD, PhD (2) · Aliae A. Hussien, MD (1) · Annetine Gelijns, PhD (1) · Danielle Antin-Ozerkis, MD (1) · David A Schwartz, MD (1) · Gregory Downey, MD (1) · Harold Collard, MD (1) · Henrik Hansen, PhD, Msc, PT (1) · Jaume Bordas-Martinez, M.D., Ph.D. (1) · Jingtao Gao, MD (1)
PMID 27462120, PMID 29754582, PMID 30616998, PMID 33072090, PMID 35120836, PMID 36481866, PMID 38386005, PMID 40461817, PMID 42548421
2018 (1), 2019 (1), 2025 (1), R01HL107882 (1), U54HL143541 (1), UG3TR002445 (1)